AGN News and Press, Allergan plc From 01/08/20

As AbbVie (NYSE: ABBV) gets closer to completing its $63 billion acquisition of Allergan (NYSE: AGN) , the company is laying out its plan for the integration. When the deal closes, which is scheduled to happen this quarter, AbbVie will keep Allergan's aesthetics as a separate unit with ...

AbbVie (NYSE: ABBV ) announces a new global business, Allergan Aesthetics, which includes BOTOX Cosmetic, Juvederm and Coolsculpting body contouring, that will be led by Allergan's current SVP, U.S. Medical Aesthetics Carrie Storm. More news on: AbbVie Inc., Allergan plc, Healthcare stoc...

AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed well lately. Over the last 12 months, AbbVie's shares are down by 2%, while Biogen's stock is down by 10%. By contrast, the pharmaceutical industry -- as measured by the SPDR S&P Pharmaceuti...

Mergers and acquisitions 2019 was the fourth biggest year on record for global M&A, with activity particularly strong in the US. Big deals were particularly common in pharmaceuticals. Bristol-Myers’ ( BMY ) consummated acquisition of Celgene resulted in a contingent value right ...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz’s abbreviated new drug application (ANDA) seeking approval to mark...

Market Performance Stocks had the second-best year since the inception of my portfolio in 1998, with ( SPY ) return including dividends of 31.0%. This was exceeded only by the 32.0% return in 2003. Bonds also enjoyed a good return as lower interest rates resulted in capital gains. ( AGG ) to...

Musings After my healthy 5% ‘alpha’ victory in 2018, 2019’s everlasting bull run was hard for my conservative portfolio to match as large cap growth stocks (which drive the S&P 500 these days) blew the doors off (+31.5%) with their best performance since 2013....

In 2019, the art of fixing the troublesome gene mutations known to cause severe, life-threatening illnesses took some big steps forward. That helped investors who began 2019 with shares of  Crispr Therapeutics (NASDAQ: CRSP) and Editas Medicine (NASDAQ: EDIT) , two gene-editing pionee...

Stocks rallied significantly in the fourth quarter, and seasonality suggests there may be additional upside, but there's also an extreme number of stocks trading at least 5% above their 200-day moving average, and Middle East saber-rattling could cause uncertainty that leads to investors der...

Allergan ( AGN -0.4% ) has settled patent infringement litigation with would-be generic competitor Maharashtra, India-based Ajanta Pharma Limited related to hypertension med Bystolic (nebivolol). More news on: Allergan plc, Healthcare stocks news, Read more ...